Skip to main content

Table 2 Selected effectiveness parameters and steroid use

From: Experience with etanercept, tocilizumab and interleukin-1 inhibitors in systemic onset juvenile idiopathic arthritis patients from the BIKER registry

JADAS-10; median (IQR)a

Month 0

Month 3

Month 6

Month 12

Month 18

Month 24

Last observation

 ETA

20.8 (14; 28.4)

6.9 (2.5; 14.3)

6.2 (1.1; 14.7)

3.8 (0.7; 15.7)

4.1 (1.5; 15.2)

3.3 (0.7; 9.4)

9.1 (2.1; 19.1)

 TOC

16.9 (8.1; 24.8)

3.6 (0.8; 10.7)

1.5 (0.2; 3.8)

1.6 (0.4; 6.7)

0.9 (0.2; 2.0)

0.9 (0.1; 7.5)

0.9 (0.1; 4)

 IL-1i

13 (6.7; 20.6)

0.8 (0.2; 1.6)

0.6 (0.2; 2.1)

0.8(0.2; 2.6)

0.2 (0; 1.9)

0.2 (0.1; 0.8)

0.8 (0.1; 5.1)

Patients with active systemic signs; n (%)b

       

 ETA

2 (1%)

0

0

2 (2.5%)

0

0

1 (1%)

 TOC

30 (42%)

5 (14%)

3 (6%)

3 (7%)

2 (5%)

1 (4%)

4 (7%)

 IL-1i

40 (63%)

9 (32%)

8 (22%)

8 (21%)

8 (26%)

4 (17%)

6 (11%)

Active joints; median (IQR)a

       

 ETA

4 (2; 11)

1 (0; 3)

1 (0; 5)

0 (0; 4)

0.5 (0; 4)

0.5 (0; 4)

1 (0; 6)

 TOC

3.0 (0; 6)

0 (0; 0.5)

0 (0; 0.3)

0 (0; 1.0)

0 (0; 0)

0 (0; 1.0)

0 (0; 0)

 IL-1i

2 (0; 5)

0 (0; 0.3)

0 (0; 0)

0 (0; 0)

0 (0; 0)

0 (0; 0)

0 (0; 0)

Patients with active joints; n (%)b

       

 ETA

121 (85%)

48 (53%)

49 (52%)

39 (48%)

36 (50%)

36 (50%)

67 (53%)

 TOC

49 (69%)

9 (26%)

12 (25%)

13 (29%)

7 (19%)

8 (29%)

15 (21%)

 IL-1i

34 (60%)

7 (25%)

6 (17%)

8 (21%)

7 (23%)

2 (9%)

12 (21%)

Patients on steroid use; n (%)b

       

 ETA

119 (83%)

66 (72%)

73 (76%)

48 (59%)

36 (49%)

35 (56%)

65 (49%)

 TOC

32 (44%)

13 (35%)

16 (31%)

7 (14%)

6 (15%)

8 (27%)

7 (11%)

 IL-1i

27 (45%)

12 (48%)

15 (45%)

10 (29%)

7 (25%)

6 (27%)

12 (24%)

  1. Data as observed
  2. JADAS Juvenile Disease Activity Score, ETA etanercept, TOC tocilizumab, IL-li interleukin-1 inhibitor
  3. aData are given as median and interquartile range of patients on treatment as observed. Note, the median value was higher in the last observation on ETA than on TOC or IL-1i
  4. bPercentage of patients reported